指南与共识泌尿男性生殖肿瘤

前列腺癌患者近距离放射治疗:美国临床肿瘤学会与加拿大安大略癌症治疗中心联合指南更新

Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.
指南 / 共识 · J Clin Oncol · 2017-03-27

该联合指南更新基于5项随机对照试验,针对不同风险分层的前列腺癌患者,明确了近距离放射治疗(单独低剂量率或作为外照射增强)的适用推荐。

要点

  • 低危患者可提供单独低剂量率近距离放射治疗、单独外照射或根治性前列腺切除术。
  • 中危患者接受外照射联合或不联合雄激素剥夺治疗时,应提供近距离放射治疗增强。
  • 高危患者接受外照射和雄激素剥夺治疗时,应提供近距离放射治疗增强。

核心结论

  • 针对低、中、高危前列腺癌患者,指南基于5项随机对照试验给出了近距离放射治疗的推荐。

研究设计与样本

  • 更新专家组进行了针对性系统文献回顾,纳入比较剂量递增外照射与近距离放射治疗的随机对照试验。

主要发现

  • 5项随机对照试验为本次更新提供了证据。

关键数值与推荐

  • 低危患者需或选择积极治疗时,应提供单独低剂量率近距离放射治疗、单独外照射和/或根治性前列腺切除术。
  • 中危患者选择外照射联合或不联合雄激素剥夺治疗时,应提供近距离放射治疗增强(低剂量率或高剂量率)。
  • 低-中危患者(Gleason 7且前列腺特异性抗原<10 ng/mL,或Gleason 6且前列腺特异性抗原10至20 ng/mL)可考虑单独低剂量率近距离放射治疗作为单一治疗。
  • 高危患者接受外照射和雄激素剥夺治疗时,应提供近距离放射治疗增强(低剂量率或高剂量率)。
  • 碘-125和钯-103均是低剂量率近距离放射治疗的合理同位素选择;对铯-131或高剂量率单一治疗无法做出推荐或反对。

临床怎么用

  • 低危前列腺癌需积极治疗者可提供单独低剂量率近距离放射治疗、单独外照射或根治性前列腺切除术。
  • 中危患者接受外照射(联合或不联合雄激素剥夺治疗)时应提供近距离放射治疗增强。
  • 低-中危特定患者可考虑单独低剂量率近距离放射治疗。
  • 高危患者接受外照射和雄激素剥夺治疗时应提供近距离放射治疗增强。
  • 低剂量率近距离放射治疗可选用碘-125或钯-103;对铯-131或高剂量率单一治疗无推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account for new evidence. Methods An Update Panel conducted a targeted systematic literature review and identified more recent randomized controlled trials comparing dose-escalated external beam radiation therapy (EBRT) with brachytherapy in men with prostate cancer. Results Five randomized controlled trials provided the evidence for this update. Recommendations For patients with low-risk prostate cancer who require or choose active treatment, low-dose rate brachytherapy (LDR) alone, EBRT alone, and/or radical prostatectomy (RP) should be offered to eligible patients. For patients with intermediate-risk prostate cancer choosing EBRT with or without androgen-deprivation therapy, brachytherapy boost (LDR or high-dose rate [HDR]) should be offered to eligible patients. For low-intermediate risk prostate cancer (Gleason 7, prostate-specific antigen < 10 ng/mL or Gleason 6, prostate-specific antigen, 10 to 20 ng/mL), LDR brachytherapy alone may be offered as monotherapy. For patients with high-risk prostate cancer receiving EBRT and androgen-deprivation therapy, brachytherapy boost (LDR or HDR) should be offered to eligible patients. Iodine-125 and palladium-103 are each reasonable isotope options for patients receiving LDR brachytherapy; no recommendation can be made for or against using cesium-131 or HDR monotherapy. Patients should be encouraged to participate in clinical trials to test novel or targeted approaches to this disease. Additional information is available at www.asco.org/Brachytherapy-guideline and www.asco.org/guidelineswiki .

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chin J, Rumble RB, Kollmeier M, et al. Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. J Clin Oncol. 2017. PMID: 28346805. doi:10.1200/JCO.2016.72.0466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。